These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 27667150)
1. The role of the kallikrein-kinin system, matrix metalloproteinases, and tissue inhibitors of metalloproteinases in the early restenosis of covered stents in the femoropopliteal arterial segment. Rocha LA; Piccinato CE; Ribiero MS; Becari C; Joviliano RD; Joviliano EE J Vasc Surg; 2017 Jan; 65(1):119-127. PubMed ID: 27667150 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty. Ribeiro MS; Dellalibera-Joviliano R; Becari C; Teixeira FR; Araujo PV; Piccinato CE; Campos CP; Evora PR; Joviliano EE Ann Vasc Surg; 2014 May; 28(4):1005-15. PubMed ID: 24440188 [TBL] [Abstract][Full Text] [Related]
3. Carbon-Coated Stent and the Role of the Kallikrein-Kinin System in Peripheral Angioplasty. Campos CP; Ribeiro MS; Rocha LA; Dellalibera-Joviliano R; Piccinato CE; Oda JMM; Joviliano EE J Vasc Res; 2020; 57(2):97-105. PubMed ID: 31896109 [TBL] [Abstract][Full Text] [Related]
4. The Role of Interleukins and Inflammatory Markers in the Early Restenosis of Covered Stents in the Femoropopliteal Arterial Segment. Guimaraes TS; da Rocha LA; Becari C; Piccinato CE; Joviliano RD; Ribeiro MS; Joviliano EE Ann Vasc Surg; 2018 Jul; 50():88-95. PubMed ID: 29481941 [TBL] [Abstract][Full Text] [Related]
5. Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty. Araújo PV; Ribeiro MS; Dalio MB; Rocha LA; Viaro F; Dellalibera Joviliano R; Piccinato CE; Évora PR; Joviliano EE Ann Vasc Surg; 2015; 29(4):731-7. PubMed ID: 25725274 [TBL] [Abstract][Full Text] [Related]
6. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year. Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773 [TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study. Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896 [TBL] [Abstract][Full Text] [Related]
8. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study. Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284 [TBL] [Abstract][Full Text] [Related]
10. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease. Chan YC; Cheng SW; Cheung GC J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015 [TBL] [Abstract][Full Text] [Related]
11. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. Shammas NW; Shammas GA; Helou TJ; Voelliger CM; Mrad L; Jerin M Cardiovasc Revasc Med; 2012; 13(4):224-7. PubMed ID: 22575073 [TBL] [Abstract][Full Text] [Related]
12. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment. Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691 [TBL] [Abstract][Full Text] [Related]